EP1071434A4 - Facteurs de liaison cnre et utilisations correspondantes - Google Patents

Facteurs de liaison cnre et utilisations correspondantes

Info

Publication number
EP1071434A4
EP1071434A4 EP99922716A EP99922716A EP1071434A4 EP 1071434 A4 EP1071434 A4 EP 1071434A4 EP 99922716 A EP99922716 A EP 99922716A EP 99922716 A EP99922716 A EP 99922716A EP 1071434 A4 EP1071434 A4 EP 1071434A4
Authority
EP
European Patent Office
Prior art keywords
cnre
binding factors
binding
factors
cnre binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99922716A
Other languages
German (de)
English (en)
Other versions
EP1071434A1 (fr
Inventor
Yuqing E Chen
Masatsugu Horiuchi
Victor J Dzau
Koichi Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP1071434A1 publication Critical patent/EP1071434A1/fr
Publication of EP1071434A4 publication Critical patent/EP1071434A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP99922716A 1998-04-24 1999-04-23 Facteurs de liaison cnre et utilisations correspondantes Withdrawn EP1071434A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8299798P 1998-04-24 1998-04-24
US82997P 1998-04-24
PCT/US1999/008502 WO1999055343A1 (fr) 1998-04-24 1999-04-23 Facteurs de liaison cnre et utilisations correspondantes

Publications (2)

Publication Number Publication Date
EP1071434A1 EP1071434A1 (fr) 2001-01-31
EP1071434A4 true EP1071434A4 (fr) 2002-04-03

Family

ID=22174781

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99922716A Withdrawn EP1071434A4 (fr) 1998-04-24 1999-04-23 Facteurs de liaison cnre et utilisations correspondantes

Country Status (4)

Country Link
EP (1) EP1071434A4 (fr)
JP (1) JP2002516664A (fr)
CA (1) CA2326622A1 (fr)
WO (1) WO1999055343A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101616A1 (fr) * 2003-05-14 2004-11-25 Sumitomo Chemical Company, Limited Proteine mutante d'epissage du recepteur x $g(a) du foie, gene correspondant et leur utilisation
JP2005034143A (ja) * 2003-06-24 2005-02-10 Sumitomo Chemical Co Ltd 肝臓Ｘ受容体αのアイソフォームである肝臓Ｘ受容体αスプライシング変異体タンパク質、その遺伝子及びそれらの利用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000242A1 (fr) * 1994-06-24 1996-01-04 Human Genome Sciences, Inc. Recepteur epsilon d'acide retinoique
WO1996021726A1 (fr) * 1995-01-13 1996-07-18 The Salk Institute For Biological Studies Identification d'une voie distincte sensible aux retinoides et ses utilisations
WO1997035018A1 (fr) * 1996-03-21 1997-09-25 New York University Serine/threonine phosphatase fin13 modulant le facteur de croissance
WO1998042738A1 (fr) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 proteines humaines secretees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000242A1 (fr) * 1994-06-24 1996-01-04 Human Genome Sciences, Inc. Recepteur epsilon d'acide retinoique
WO1996021726A1 (fr) * 1995-01-13 1996-07-18 The Salk Institute For Biological Studies Identification d'une voie distincte sensible aux retinoides et ses utilisations
WO1997035018A1 (fr) * 1996-03-21 1997-09-25 New York University Serine/threonine phosphatase fin13 modulant le facteur de croissance
WO1998042738A1 (fr) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 proteines humaines secretees

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9955343A1 *
WILLY P J ET AL: "UNIQUE REQUIREMENTS FOR RETINOID-DEPENDENT TRANSCRIPTIONAL ACTIVATION BY THE ORPHAN RECEPTOR LXR", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 11, no. 3, 1 February 1997 (1997-02-01), pages 289 - 298, XP000905096, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
EP1071434A1 (fr) 2001-01-31
JP2002516664A (ja) 2002-06-11
CA2326622A1 (fr) 1999-11-04
WO1999055343A1 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
EP0790826A4 (fr) Dihydropyrimidines et leurs utilisations
DE69943335D1 (de) Ionenleitende matrizen und deren verwendung
DE69913169D1 (de) Sportschuh und dafür vorgesehene dornen
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
NO991151D0 (no) Forbindelse og anvendelse derav
EP1085887A4 (fr) Nouveaux modulateurs des r cepteurs de l'angiotensine et leurs utilisations
DE69720774D1 (de) S-omeprazol in festform
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
PT1120392E (pt) Catalisador e composicao organometalica
ATE220304T1 (de) Servier- und transportaufnahme
DK1112003T3 (da) Ny sammensætning og anvendelse
DE69724629D1 (de) Zusammensetzungen und deren verwendungen
ATE227724T1 (de) Muscarinagonisten und antagonisten
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
DE69917261D1 (de) Photoinitiatoren und ihre verwendungen
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE69724367D1 (de) Polyarylensulfid und zusammensetzung
DE50011452D1 (de) Polyalkenalkohol-polyalkoxylate und deren verwendung in kraft- und schmierstoffen
DE69716696D1 (de) Vielfächiger ordner und multi-ordner
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
DE60036885D1 (de) Succinimidverbindungen und deren verwendung
DE69900802D1 (de) MnMgCuZn-Ferrit und dessen Verwendung
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020220

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/70 A, 7A 61K 38/17 B, 7A 61K 39/00 B, 7C 07H 21/00 B, 7C 07H 21/04 B, 7C 12N 5/06 B, 7C 12N 5/16 B, 7C 12N 15/85 B, 7C 12Q 1/68 B, 7C 07K 14/705 B

17Q First examination report despatched

Effective date: 20040517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040928